Research into the mechanism of endocrine responsiveness and resistance in breast and gynecologic cancers has revealed that the PI3K/AKT/mTOR pathway becomes activated and utilized by cancer cells to bypass the effects of hormone therapy [11-13]. The gene discussed is MTOR; the disease is female reproductive organ cancer.